BridgeBio Pharma Quarterly Balance Sheet
NASDAQ: BBIOHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BridgeBio Pharma financial position
As of Jun 30, 2026, BridgeBio Pharma reported total assets of $1.22 billion, up 12.7% from a year earlier against total liabilities of $3.72 billion. Shareholders' equity was negative at -$2.52 billion, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $677.9 million in cash and equivalents against $2.65 billion of debt, a net debt position of $1.97 billion.
The current ratio (current assets divided by current liabilities) was 1.23, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
BridgeBio Pharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 677.91M | 879.89M | 570.12M | 642.95M | 748.95M | 540.60M | 681.10M | 266.32M | 407.96M | 475.22M | 375.94M | 505.21M |
| Short-Term Investments | 42.25M | 60.30M | 17.36M | 2.99M | 7.94M | — | 0 | — | 39.81M | 44.47M | 0 | 0 |
| Receivables | 254.48M | 205.23M | 139.44M | 116.52M | 76.87M | 115.27M | 4.72M | — | — | — | 1.75M | — |
| Inventory | 52.84M | 32.98M | 26.75M | 24.53M | 18.28M | 3.95M | 0 | — | — | — | — | — |
| Total Current Assets | 1.09B | 1.24B | 797.75M | 839.38M | 912.28M | 695.17M | 720.69M | 444.58M | 616.24M | 783.42M | 477.59M | 587.67M |
| Property, Plant & Equipment | 5.23M | 4.94M | 5.37M | 5.83M | 6.11M | 6.70M | 7.01M | 8.70M | 9.84M | 11.41M | 11.82M | 12.41M |
| Intangible Assets | 26.64M | 27.36M | 28.08M | 28.80M | 29.51M | 27.80M | 23.93M | 24.52M | 25.12M | 25.72M | 26.32M | 26.92M |
| Total Assets | 1.22B | 1.37B | 936.02M | 998.25M | 1.08B | 881.64M | 919.34M | 664.98M | 794.38M | 849.33M | 546.38M | 655.01M |
| Accounts Payable | 27.20M | 29.06M | 36.23M | 18.70M | 26.13M | 27.52M | 9.62M | 13.36M | 18.13M | 4.73M | 10.65M | 4.47M |
| Total Current Liabilities | 890.65M | 816.37M | 287.97M | 216.60M | 175.85M | 152.10M | 154.40M | 139.22M | 134.36M | 141.48M | 143.84M | 106.06M |
| Long-Term Debt | 2.65B | 2.65B | 2.01B | 2.01B | 0 | 0 | 437.34M | 436.22M | 435.45M | 434.72M | 446.44M | 441.72M |
| Total Liabilities | 3.72B | 3.64B | 3.01B | 2.92B | 2.86B | 2.52B | 2.38B | 1.88B | 1.88B | 1.89B | 1.89B | 1.85B |
| Shareholders' Equity | -2.52B | -2.28B | -2.09B | -1.93B | -1.79B | -1.65B | -1.47B | -1.23B | -1.09B | -1.05B | -1.35B | -1.21B |
| Retained Earnings | -4.14B | -3.99B | -3.82B | -3.63B | -3.45B | -3.26B | -3.10B | -2.83B | -2.67B | -2.60B | -2.56B | -2.39B |
| Total Debt | 2.65B | 2.65B | 2.01B | 2.01B | 0 | 0 | 437.34M | 436.22M | 435.45M | 434.72M | 446.44M | 441.72M |
| Net Cash (Debt) | -1.93B | -1.71B | -1.42B | -1.36B | 756.89M | 540.60M | 243.76M | -169.90M | 12.32M | 84.97M | -70.51M | 63.49M |
| Shares Outstanding | 195.28M | 195.71M | 194.77M | 192.63M | 191.16M | 189.83M | 190.04M | 188.99M | 188.03M | 187.12M | 175.08M | 174.13M |
This table shows 12 quarterly periods of BridgeBio Pharma's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BBIO's reporting calendar. What is a balance sheet?